Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Iqbal, Danish ^a   Khan, M Salman ^a   Khan, Mohd Sajid ^a   Ahmad, Saheem ^a   Hussain, Md Sarfaraj ^a   Ali, Mohd ^b  

^a INTEGRAL UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Antioxidant; Ficus virens; HMG CoA reductase; Hyperlipidemia; Inhibitor; Molecular Docking

Indexed keywords

ATORVASTATIN; FICUS VIRENS EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N OCTADECANYL O ALPHA DEXTRO GLUCOPYRANOSYL (6'-1'') O ALPHA DEXTRO GLUCOPYRANOSIDE; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PRAVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; DISACCHARIDE; GLYCOLIPID; N-OCTADECANYL-O-GLUCOPYRANOSYL-(6'-1')-O-GLUCOPYRANOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOACTIVITY GUIDED FRACTIONATION; CARBON NUCLEAR MAGNETIC RESONANCE; COLUMN CHROMATOGRAPHY; COMPUTER MODEL; CONTROLLED STUDY; DPPH RADICAL SCAVENGING ASSAY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG ISOLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETIC ASSAY; FICUS; FICUS VIRENS; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; FRACTIONATION; HYPERLIPIDEMIA; HYPOLIPIDEMIC ACTIVITY; IC50; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MASS SPECTROMETRY; MOLECULAR DOCKING; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BARK; BLOOD; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HYPERLIPIDEMIAS; ISOLATION AND PURIFICATION; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

FICUS VIRENS; RATTUS;

ANIMALS; ANTIOXIDANTS; CHEMICAL FRACTIONATION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISACCHARIDES; FICUS; GLYCOLIPIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIVER; MALE; PLANT BARK; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 85018117560     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0013-6     Document Type: Article

References (69)

1. Leeder S, Raymond S, Greenberg H, Liu H, Esson K. A race against time: the challenge of cardiovascular disease in developing countries. New York: Trustees of Columbia University; 2004.
2. Guilbert JJ. The world health report 2002-reducing risks, promoting healthy life. Educ Health (Abingdon). 2003;16:230.
3. Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-478.
4. Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res. 1998;39:1008-20.
5. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-7.
6. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res. 1980;21:505-17.
7. Carbonell T, Freire E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry. 2005;44:11741-8.
8. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995;31:9-27.
9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366(9493):1267-78.
10. Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28:625-34.
11. Oorni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen PT. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol. 2005;25:1678-83.
12. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol. 2005;8:95-7.
13. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858-68.
14. Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care. 2013;36:422-8.
15. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot (Japan). 1976;29:1346-8.
16. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-82.
17. Anandjiwala S, Bagul MS, Parabia M, Rajani M. Evaluation of free radical scavenging activity of an Ayurvedic formulation Panchvalakala. Indian J Pharm Sci. 2008;70:31-5.
18. Shi YX, Xu YK, Hu HB, Na Z, Wang WH. Preliminary assessment of antioxidant activity of young edible leaves of seven Ficus species in the ethnic diet in Xishuangbanna, Southwest China. Food Chem. 2011;128:889-94.
19. Hameed ESSA. Total phenolic contents and free radical scavenging activity of certain Egyptian Ficus species leaf samples. Food Chem. 2009;114:1271-7.
20. Iqbal D, Khan MS, Khan MS, Ahmad S, Srivastava AK. An in vitro and molecular informatics study to evaluate the antioxidative and β-hydroxy-β-methylglutaryl-CoA reductase inhibitory property of Ficus virens Ait. Phytother Res. 2013. doi:10.1002/ptr.5077.
21. Williams BW, Cuvelier ME, Berset C. Use of free radical method to evaluate antioxidant activity. LWT. 1995;28:25-30.
22. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239:70-6.
23. Wong CC, Li HB, Cheng KW, Chen FA. Systematic survey of antioxidant activity of 30 Chinese medicinal plants using the ferric reducing antioxidant power assay. Food Chem. 2006;97:705-11.
24. Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Amer Chem Soc. 1934;56:658.
25. Dixon M. The determination of enzyme inhibitor constants. Biochem J. 1953;55:170-1.
26. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit. 1996;9:1-5.
27. Huey R, Morris GM, Olson AJ, Goodsell DSA. Semiempirical free energy force field with charge based desolvation. J Comput Chem. 2007;28:1145-52.
28. Cheng A, Merz KM. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure property relationships. J Med Chem. 2003;46:3572-80.
29. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999;16:1514-9.
30. Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL. Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem. 2001;44:4370-8.
31. Egan WJ, Merz KMJR, Baldwin J. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000;43:3867-77.
32. Susnow RG, Dixon SL. Use of robust classification techniques for of human cytochrome P450 2D6 inhibition. J Chem Inform Comp Sci. 2003;43:1308-15.
33. Hafeez A, Jain U, Sajwan P, Srivastava S, Thakur A. Evaluation of Carrageenan induced anti-inflammatory activity of ethanolic extract of bark of Ficus virens Linn. in swiss albino mice. J Phytopharmacol. 2013;2:39-43.
34. Jayashree P, Shridhar NB, Vijaykumar M, Suhasini KJ, Satyanarayana ML. Toxicological studies of Ficus Virens in Wistar Albino Rats. Int Res J Pharmacy. 2012;3:84-7.
35. Harnafi H, El-Houda-Bouanani N, Aziz M, Caid HS, Ghalim N, Amrani S. The hypolipidaemic activity of aqueous Erica multiflora flowers extract in Triton WR-1339 induced hyperlipidaemic rats: a comparision with fenofibrate. J Ethnopharmacol. 2007;109:156-60.
36. Kumar V, Khan MM, Khanna AK, Singh R, Singh S, Chander R, et al. Lipid lowering activity of Anthocephalus indicus root in hyperlipidemic rats. Evid Based Complement Alternat Med. 2010;7:317-22.
37. Wieland H, Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res. 1983;24:904-9.
38. 3 in human plasma. Clin Chem. 1989;35:265-70.
39. Trinder P. Quantitative determination of triglyceride using GPO-PAP method. Ann Biochem. 1969;6:24-7.
40. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
41. Rao V, Ramakrishnan A. Indirect assessment of hydroxyl methyl gultaryl CoA reductase (NAOPH) activity in liver tissue. Clin Chem. 1975;21:1523-5.
42. Ahmad S, Shahab U, Baig MH, Khan MS, Khan MS, Srivastava AK, et al. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PLoS One. 2013;8(9):e72128.
43. Iqbal D, Khan MS, Khan A, Khan MS, Ahmad S, Srivastava AK, et al. In vitro screening for β-hydroxy-β-methylglutaryl-coa reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk. BioMed Res Int. 2014;Article ID 762620:1-10. http://dx.doi.org/10.1155/2014/762620.
44. Visavadiya NP, Narasimhacharya AVRL. Asparagus root regulates cholesterol metabolism and improves antioxidant status in hypercholesteremic rats. Advance Access Publication. 2009;6:219-26.
45. Da Silva VB, Taft CA, Silva CHTP. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. J Phys Chem A. 2008;112:2007-11.
46. Naruszewicz M, Laniewska I, Millo B, Dluzniewski M. Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infarction (MI). Atherosclerosis. 2007;194:e179-84. doi:10.1016/j.atherosclerosis.2006.12.032.
47. George TW, Niwat C, Waroonphan S, Gordon MH, Lovegrove JA. Effects of chronic and acute consumption of fruit-and vegetable-puree-based drinks on vasodilation, risk factors for CVD and the response as a result of the eNOS G298T polymorphism. Proc Nutr Soc. 2009;68:148-61.
48. Clifton PM. Effect of grape seed extract and quercetin on cardiovascular and endothelial parameters in high-risk subjects. J Biomed Biotechnol. 2004;5:272-8.
49. Shahidi F, Janitha PK, Wanasundara PD. Phenolic antioxidants. Crit Rev Food Sci Nutr. 1992;202:307.
50. Jung KA, Song TC, Han D, Kim IH, Kim YE, Lee CH. Cardiovascular protective properties of Kiwifruit extracts in vitro. Biol Pharm Bull. 2005;28:1782-5.
51. Gholamhoseinian A, Shahowzehi B, Far FS. Inhibitory activity of some plant methanol extracts on 3-Hydroxy-3-Methylglutaryl coenzyme A reductase. Int J Pharmacol. 2010;6:705-11.
52. Qureshi AA, Burgerpll WC, Petersonpll DM, Elson CE. The structure of an inhibitor of cholesterol biosynthesis isolated from barley. J Biol Chem. 1986;261:10544-50.
53. Min SW, Kim DH. Kakkalide and irisolidone: HMG-CoA reductase inhibitors isolated from the flower of Pueraria thunbergiana. Biol Pharm Bull. 2007;30:1965-8.
54. Vallianou I, Peroulis N, Pantazis P, Cladaras HM. Camphene, a plant-derived monoterpene, reduces plasma cholesterol and triglycerides in hyperlipidemic rats independently of HMG-CoA reductase activity. PLoS One. 2011;6:11. e20516.
55. Kim HJ, Lee DH, Hwang YY, Lee KS, Lee JS. Characterization of β-Hydroxy-β methylglutaryl Coenzyme A reductase inhibitor from Pueraria thunbergiana. J Agric Food Chem. 2005;53:5882-8.
56. Patil AD, Chan JA, Lois-Flamberg P, Mayer RJ, Westley JW. Novel acetylenic acids from the root bark of Paramacrolobium caeruleum: inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A reductase. J Nat Prod. 1989;52:153-61.
57. Kwon EK, Lee DY, Lee H, Kim DO, Baek NI, Kim YE, et al. Flavonoids from the buds of Rosa damascena inhibit the activity of 3-Hydroxy-3-methylglutaryl-coenzyme A reductase and angiotensin I-converting enzyme. J Agric Food Chem. 2010;58:882-6.
58. Khan MS, Akhtar S, Al-Sagair OA, Arif JM. Protective Effect of dietary tocotrienols against infection and inflammation-induced hyperlipidemia: an in vivo and in silico study. Phytother Res. 2011;25:1586-95.
59. Khanna AK, Rizivi F, Chander R. Lipid lowering activity of Phyllanthus niruri in hyperlipidemic rats. J Ethnopharmacol. 2002;82:19-32.
60. Kuroda M, Tanzawa K, Tsujita Y, Endo A. Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in Triton WR-1339 induced hyperlipidemia. Biochim Biophys Acta. 1997;489:119-25.
61. Venkadeswaran K, Muralidharan AR, Annadurai T, Ruban VV, Sundararajan M, Anandhi R, et al. Antihypercholesterolemic and antioxidative potential of an extract of the plant, Piper betle, and its active constituent, eugenol, in Triton WR-1339 induced hypercholesterolemia in experimental rats. Evid Base Complement Alternat Med. 2014;Article ID 47897:1-11. http://dx.doi.org/10.1155/2014/478973.
62. Schotz MC, Seanu A, Page IH. Effect of triton on lipoprotein lipase of rat plasma. Am J Physiol. 1957;188:399-402.
63. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152-4.
64. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-91.
65. Drexel H, Amann FW, Rentsch K, Neuenschwander C, Luethy A, Khan SI, et al. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol. 1992;70:436-40.
66. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-22.
67. Kandutsch AA, Saucier SE. Prevention of cyclic and triton-induced increases in hydroxymethylglutaryl Coenzyme A reductase and sterol synthesis by puromycin. J Biol Chem. 1969;244:2299-305.
68. Goldfarb S. Rapid increases in hepatic HMG CoA reductase activity and in vivo cholesterol synthesis after Triton WR 1339 injection. J Lipid Res. 1978;19:489-94.
69. Sashidhara KV, Singh SP, Srivastava A, Puri A, Chhonker YS, Bhatta RS, et al. Discovery of a new class of HMG-CoA reductase inhibitor from Polyalthia longifolia as potential lipid lowering agent. Eur J Med Chem. 2011;46:5206-11.